DDInter1610 DDInter1925
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Rivastigmine {u} (Compound) upregulates {v} (Gene) ST6GALNAC2
ST6GALNAC2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Rivastigmine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Rivastigmine {u} (Compound) upregulates {v} (Gene) ST6GALNAC2
ST6GALNAC2 {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Vemurafenib
Rivastigmine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is regulated by {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Vemurafenib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Myalgia
Myalgia {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Electrocardiogram QT prolonged
Electrocardiogram QT prolonged {u} (Side Effect) is caused by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Rivastigmine (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Vemurafenib (Compound)
Rivastigmine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Vemurafenib (Compound)
Rivastigmine (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Rivastigmine (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Vemurafenib (Compound)
Rivastigmine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is regulated by ALB (Gene) and ALB (Gene) is bound by Vemurafenib (Compound)
Rivastigmine (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Rivastigmine (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Rivastigmine (Compound) causes Electrocardiogram QT prolonged (Side Effect) and Electrocardiogram QT prolonged (Side Effect) is caused by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib